Zanubrutinib (Brukinsa®) is indicated as monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/10/2021|
|Rapid review completed||16/11/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.